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Notch signaling has been identified as a critical pathway in 
gastric cancer (GC) progression and metastasis, and inhibition 
of Delta-like ligand 4 (DLL4), a Notch ligand, is suggested as a 
potent therapeutic approach for GC. Expression of both DLL4 
and vascular endothelial growth factor receptor 2 (VEGFR2) 
was similar in the malignant tissues of GC patients. We focu-
sed on vascular endothelial growth factor (VEGF), a known 
angiogenesis regulator and activator of DLL4. Here, we used 
ABL001, a DLL4/VEGF bispecific therapeutic antibody, and in-
vestigated its therapeutic effect in GC. Treatment with human 
DLL4 therapeutic antibody (anti-hDLL4) or ABL001 slightly re-
duced GC cell growth in monolayer culture; however, they 
significantly inhibited cell growth in 3D-culture, suggesting a 
reduction in the cancer stem cell population. Treatment with 
anti-hDLL4 or ABL001 also decreased GC cell migration and 
invasion. Moreover, the combined treatment of irinotecan with 
anti-hDLL4 or ABL001 showed synergistic antitumor activity. 
Both combination treatments further reduced cell growth in 
3D-culture as well as cell invasion. Interestingly, the combina-
tion treatment of ABL001 with irinotecan synergistically reduced 
the GC burden in both xenograft and orthotopic mouse mo-
dels. Collectively, DLL4 inhibition significantly decreased cell 
motility and stem-like phenotype and the combination treat-
ment of DLL4/VEGF bispecific therapeutic antibody with irino-
tecan synergistically reduced the GC burden in mouse models. 
Our data suggest that ABL001 potentially represents a potent 
agent in GC therapy. Further biochemical and pre-clinical studies 
are needed for its application in the clinic. [BMB Reports 
2020; 53(10): 533-538]
INTRODUCTION
Gastric cancer (GC) is one of the most common malignancies, 
accounting for more than one million newly diagnosed cases 
each year worldwide (1, 2). Although the key molecular signal-
ing pathways in GC have been researched extensively, the mole-
cules associated with GC have not been identified (3). A few 
molecular-guided targeted therapies have been developed and 
are being widely used in the clinical treatment of patients with 
advanced-stage of GC; however, the overall survival remains 
poor (4). Therefore, further research into the molecular mecha-
nisms in GC and novel anti-cancer drugs are needed for effec-
tive molecular-targeted therapy. 
The Notch signaling pathway has been implicated in cancer 
cell survival, metastasis, drug resistance through the mainte-
nance of cancer stem cells (CSCs), epithelial–mesenchymal tran-
sition (EMT), and genomic instability (5, 6). In mammals, there 
are four Notch homologous receptors (Notch 1-4), which can 
bind various ligands–Delta-like ligands (DLL1, 3, and 4), and 
Jagged 1 and 2 (7). DLL4, one of the major factors involved in 
Notch signaling, was shown to be responsible for tumor for-
mation, EMT, and self-renewal as CSCs (8). Targeting DLL4 expres-
sion may be a feasible approach to interfere with angiogenesis, 
tumorigenesis, and metastasis for anti-cancer effect (9, 10). 
However, the clinical significance of DLL4 expression in GC is 
associated with poor prognosis (9) but mechanistic details re-
main unresolved (11).
Here, we analyzed the therapeutic potential of DLL4 inhibi-
tion using an anti-human DLL4 therapeutic antibody and ABL001, 
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Fig. 1. DLL4 and VEGFR2 expression and the associated survival 
rate in GC patients, and viability of GC cell lines following treatment 
with anti-human DLL4 or ABL001 antibody. (A) DLL4 and VEGFR2 
expression was analyzed in the malignant tissues of GC patients from 
the cBioPortal database. (B) Kaplan-Meier survival plots demonstrating 
poor prognostic value of DLL4 and VEGFR2 up-regulation, which 
correlates with a worse overall survival of GC patients. (C) Twelve 
GC cell lines were treated with different concentrations of anti-hDLL4 
and ABL001 for 24 h. Cell viability was then analyzed using WST 
assay and the assays were performed in triplicate.
a DLL4/VEGF bispecific therapeutic antibody in GC. The ABL001 
bispecific antibody consists of an anti-VEGF antibody (bevacizumab- 
like) backbone C-terminally linked with a DLL4-targeting single- 
chain variable fragment which shows potent binding affinity to 
VEGF (12), suggesting that it may be a novel therapeutic anti-
body for cancer treatment. We also assessed the synergistic 
therapeutic effect of the combination treatment of ABL001 and 
irinotecan on GC using both xenograft and orthotopic mouse 
models. Irinotecan is a key chemotherapeutic drug in several 
cancers (13) and mediates its effect by inducing DNA damage 
and cell death through topoisomerase 1 activity inhibition. Re-
cently, irinotecan has been used for advanced GC treatment as 
single agent (14) and in combination with 5-FU (15, 16). There-
fore, we focused on the synergistic effect of combination treat-
ment of irinotecan and ABL001 in GC.
RESULTS
DLL4 and VEGFR2 expression and their association with 
survival of GC patients
DLL4 and VEGFR2 expression in malignant stomach tissues of 
GC patients was obtained from the cBioPortal database (Fig. 
1A). Moreover, we performed Kaplan-Meier analysis to generate 
a survival curve of the analyzed gene sets (low and high 
expression groups of both DLL4 and VEGFR2) of GC patients 
(Fig. 1B). Statistical analysis showed that high DLL4 and 
VEGFR2 expression correlated with lower survival. Therefore, 
we hypothesized that high DLL4 and VEGFR2 expression was 
related to GC progression.
Growth inhibition of GC cell lines following treatment with 
anti-human DLL4 or ABL001 
We treated twelve GC cell lines with the indicated doses (Fig. 
1C) of anti-human DLL4 (anti-hDLL4) and bispecific DLL4/ 
VEGF therapeutic antibody (ABL001) for 3 days. Anti-DLL4 medi-
ated dose-dependent growth inhibition of AGS and MKN28 
GC cells. ABL001 also mediated dose-dependent growth inhi-
bition of AGS, MKN28, and NCI-N87 GC cells. We determined 
the expression of Notch 1 and 2, DLL4, Hes1, and VEGFR2 at the 
mRNA level in the twelve GC cell lines (Supplementary Fig. 
1). Notch receptor 1 and 2 expression was detected in all the 
GC cells. AGS cells showed expression of both DLL4 and 
VEGFR2, whereas MKN28 cells showed high DLL4 expression 
with low VEGFR2 expression, suggesting that AGS cells were 
sensitive to both anti-hDLL4 and ABL001, while MKN28 cells 
were sensitive to anti-hDLL4. Therefore, we selected AGS cells, 
which were the most sensitive to both anti-hDLL4 and ABL001, 
and MKN28 cells, which were the most sensitive to anti-hDLL4 
for further studies.
Cell cycle inhibition and apoptosis induction in GC cell lines 
following treatment with anti-human DLL4 or ABL001 
We choose AGS and MKN28 GC cells to assess the cell cycle 
status following treatment with 50 nM anti-hDLL4 or ABL001 
for 24 hr to analysis cell cycle population (Fig. 2A). Both the 
antibodies inhibited cell growth, but did not affect the cell cycle 
arrest in either AGS or MKN28 cells on day 1. Apoptosis was 
assessed following 24 h treatment with 50 nM anti-hDLL4 or 
ABL001. Neither of the cell lines showed apoptosis induction 
following treatment (Fig. 2B). These data suggested that neither 
anti-hDLL4 nor ABL001 directly affects cell cycle and apoptosis 
of the GC cells.
Cell invasion, migration, and stem-like phenotype of GC cell 
lines following treatment with anti-human DLL4 or ABL001
We treated AGS and MKN28 cells with 50 nM anti-hDLL4 or 
ABL001 and assessed cell motility (Fig. 2C and 2D) and stem-
ness (Fig. 2E). Treatment of the cells with anti-hDLL4 and ABL 
001 for 1 d significantly decreased invasion (Fig. 2C) and migra-
tion (Fig. 2D) in both the cell lines. The decrease in migration 
and invasion was greater in AGS than in MKN28 cells. More-
over, in 3D-culture, AGS and MKN28 cells were treated with 
anti-hDLL4 and ABL001 for 15 days (Fig. 2D). The number and 
size of the spheres were markedly reduced following treatment 
with anti-hDLL4 and ABL001 in both the cells, suggesting that 
anti-hDLL4 and ABL001 treatment decreased stem-like pheno-
typic character of the GC cells. Further, the decrease in the 
motility and stem-like phenotype was higher in AGS than in 
MKN28 cells with both anti-hDLL4 and ABL001; however, 
there was no difference in the sensitivity of the two cell lines 
to anti-hDLL4 and ABL001 in an in vitro culture system.
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Fig. 2. Cell cycle distribution, apoptosis, cell invasion, migration, 
and stem-like phenotype following treatment with anti-human DLL4 
or ABL001 antibody in GC cells (A, B) AGS and MKN28 GC 
cells were treated with 50 nM anti-hDLL4 or ABL001 for 24 h. 
(A) Cell cycle distribution was detected by PI staining and FACS 
analysis. (B) Apoptosis induction was detected with Annexin V and 
17-AAD staining and FACS analysis. (C, D) AGS and MKN28 GC 
cells were prepared and added to Transwell chambers. (C) The 
upper side of the membrane was coated with collagen type I for 
migration assay. (D) The lower side of the membrane was coated 
with Matrigel for invasion assay. After incubation with 50 nM anti- 
hDLL4 or ABL001 for 24 h, the migrated or invaded cells in the 
lower chamber were quantified following H&E staining by counting 
in five randomly selected areas in each well using wide-field micro-
scopy. Data are expressed as mean ± standard error of mean (SEM) 
from three independent experiments. (E) AGS and MKN28 cells (1,000 
cells each) were grown in ultra-low attachment plates containing mam-
mary epithelium basal medium supplemented with or without anti- 
hDLL4 or ABL001. After culturing for 15 d, spheres with diameters 
of ＞ 50 m were counted. Cells were treated every 3 days with 
50 nM concentration of the antibodies. *P ＜ 0.05, **P ＜ 0.01, 
and *** P ＜ 0.001.
Fig. 3. Cell viability following combination treatment with irinotecan 
and anti-human DLL4 therapeutic antibody or irinotecan and ABL 
001 antibody in GC cells (A, B) AGS and MKN28 cells were 
treated with 1 M irinotecan alone, a combination of irinotecan (0.5 
M) and anti-hDLL4 (25 nM), or irinotecan (0.5 M) and ABL001 
(25 nM) for 24 h. (A) WST assays were performed to detect the 
cell viability. (B) Invasion ability of the cells was analyzed using 
Transwell chamber assay. (C, D) AGS and MKN28 cells were 
grown under 3D-culture conditions and the sphere-forming ability 
was measured after 15-days of treatment. Cells were treated with 
1 M irinotecan alone, a combination of irinotecan (0.5 M) and 
anti-hDLL4 (25 nM), or irinotecan (0.5 M) and ABL001 (25 nM) 
every 3 days. *P ＜ 0.05, **P ＜ 0.01, and *** P ＜ 0.001.
Synergistic effect of the combination of anti-human DLL4 or 
ABL001 with irinotecan in GC cells
To test the practical applicability of anti-hDLL4 and ABL001 in 
GC therapy, we evaluated the effect of combination treatment 
of anti-hDLL4, ABL001, and irinotecan in GC cells. AGS and 
MKN45 cells were treated with 1 M of irinotecan alone, or a 
combination of irinotecan (0.5 M) with anti-hDLL4 (25 nM), 
or irinotecan (0.5 M) with ABL001 (25 nM) for 2 days. Both 
the combination treatments showed greater inhibition of cell 
viability compared to treatment with irinotecan alone in AGS 
cells, but not in MKN28 cells (Fig. 3A). We also evaluated the 
inhibitory effect of the combined treatments on cell invasion. 
Cell invasion was slightly reduced following treatment with 
irinotecan alone, but the combination treatments induced sig-
nificant inhibition of cell invasion (Fig. 3B). 
Next, we determined the effect of the combination treat-
ments on sphere-forming ability of AGS and MKN45 cells by 
performing 3D cell culture assays (Fig. 3C and 3D). Cultivation 
of the cells in sphere-forming culture media revealed that the 
size and number of spheres were smaller in both the combi-
nation treatments compared to treatment with irinotecan alone. 
These data suggested that both anti-hDLL4 and ABL001 show 
enhanced therapeutic effect on GC cells when used in combi-
nation with irinotecan.
Synergistic effect of the combination of irinotecan and 
anti-mouse surrogate ABL001 in GC-bearing mouse models
Next, we sought to determine the in vivo therapeutic effect of 
combination treatment with mouse ABL001 (mABL001) and 
irinotecan in a GC mouse model. We used mouse surrogate 
ABL001 in the mouse cancer model, because ABL001 would 
affect DLL4 and VEGF in the cancer tissues of the mouse 
models. Palpable xenografted gastric tumors were generated 
using AGS cells and the mice were administered 3.25 mg/kg 
mABL001, 10 mg/kg irinotecan, and a combination of 3.25 
mg/kg mABL001 and 10 mg/kg irinotecan through intraperito-
neal (i.p.) injection twice a week (Supplementary Fig. 2). Treat-
ment with irinotecan alone did not affect the tumor growth 
and the tumor burden was similar to that of the control, wher-
eas treatment with ABL001 significantly decreased the tumor 
burden. Interestingly, combination treatment with irinotecan 
and ABL001 synergistically decreased the tumor burden more 
than either of the treatments alone (Fig. 4A). After the mice 
were euthanized, the tumors were resected, photographed 
(Fig. 4B), and weighed (Fig. 4C). The synergistic effect of the 
combination treatment with irinotecan and ABL001 is shown 
in Fig. 4A. 
Furthermore, we used an orthotopic GC mouse model, which 
more closely mimics the physiology of human GCs, because 
the sensitivity of therapeutic effect is distinct in the different 
locations and organs in the body. In vivo bioluminescence 
Synergistic antitumor effect of ABL001/irinotecan
Da-Hyun Kim, et al.
536 BMB Reports http://bmbreports.org
Fig. 4. Synergistic effect of combination treatment of irinotecan 
and anti-mouse surrogate ABL001 antibodies in GC-bearing mouse 
model. (A-C) AGS cells (1 × 106) were injected subcutaneously in 
nude mice (n = 5). Once palpable tumors were detectable, the 
mice were administrated 200 l PBS (as control), 3.25 mg/kg ABL 
001, 10 mg/kg irinotecan, or a combination of 3.25 mg/kg ABL001 
and 10 mg/kg irinotecan by intraperitoneal (i.p.) injection twice a 
week. (A) Tumor size was measured every week for 5 weeks and 
presented graphically. (B) At the end of the treatment, the mice 
were euthanized and tumors were excised and photographed. (C) 
Tumors were weighed and the results were presented as bar graph. 
(D-F) Luciferase gene-transfected AGS cells were injected subcuta-
neously in nude mice and allowed to grow. The palpable tumor 
was excised and cut into sections of 10 mm3. A section of the 
tumor was surgically transplanted in the stomach walls of fresh nude 
mice (n = 5). After establishment of orthotopic gastric tumors, the 
mice were administered 200 l PBS (as control), 10 mg/kg irino-
tecan, or a combination of 3.25 mg/kg ABL001 and 10 mg/kg irino-
tecan through intraperitoneal (i.p.) injection twice a week for 5 
weeks. (D) In vivo bioluminescent imaging of the tumor growth in 
mice. (B) Mice were euthanized and the orthotopic gastric tumors 
were excised and photographed. (C) Tumor growth was quantified 
by measuring the tumor weight and volume and results were pre-
sented as graphs. *P ＜ 0.05, **P ＜ 0.01, and *** P ＜ 0.001.
imaging by luciferase labeling is useful in analyzing cancer 
cells and monitoring tumor growth (17). We generated xeno-
graft tumors of these cells in mice. The tumors were then 
excised, cut into 10 mm3 sections, and surgically implanted 
into the stomach epithelia of the mice. After confirming that 
the orthotopic gastric tumors were established in the stomach 
of the animals, the mice were administered 3.25 mg/kg mABL001, 
10 mg/kg irinotecan, and a combination of 3.25 mg/kg mABL001 
and 10 mg/kg irinotecan through i.p. injection twice a week 
for 4 weeks (Supplementary Fig. 3). The orthotopic tumor growth 
in mouse stomach was measured by tomographic imaging (Fig. 
4D), the orthotopic tumors were excised, photographed (Fig. 
4E), and their weights and volumes were measured (Fig. 4F). 
The therapeutic effect of the combination treatment of irinote-
can with mABL001 was greater than that of either of the single 
treatments or PBS treatment. The decrease in tumor weight and 
volume was the most significant in the combination treatment 
with irinotecan and mABL001 than in either of the single 
treatments or that observed in the xenograft mouse model 
described earlier. Interestingly, the treatment with irinotecan alone 
had better therapeutic effect in the orthotopic GC mouse model 
than in the xenograft GC mouse model, whereas mABL001 
had consistent therapeutic effect in both the GC mouse 
models. These results strongly suggested that ABL001 has anti- 
cancer effect in GC mouse models and that the combination 
treatment of irinotecan and ABL001 has synergic anti-GC effect.
DISCUSSION
Despite surgical resection and systemic chemotherapy, advanced- 
stage GC patients with distant metastasis continue to have poor 
prognosis (18, 19). 5-FU and cisplatin are the major drug used 
in GC treatment and anti-cancer drugs are often combined for 
GC treatment (20). Irinotecan, is a key chemotherapeutic drug 
used in combination treatment with 5-FU for metastatic colorectal 
cancer (21). Irinotecan induces DNA damage and cell death 
through the inhibition of topoisomerase 1 activity. Recently, 
irinotecan has been used to treat advanced-stage GC as single 
treatment (14, 16) or in combination with other agents (22, 23). 
In this study, we determined the inhibition of DLL4 to be a 
potent approach in GC therapy. We were especially interested 
in therapeutic effect of ABL001, a DLL4 and VEGF bispecific 
therapeutic antibody in GC. ABL001 competitively inhibited 
the binding of ligands to their corresponding receptors, includ-
ing that of DLL4 to Notch1 and VEGF to VEGFR2 (12). DLL4 is 
a Notch ligand that regulates the activity of the Notch pathway 
and its expression highly correlates with tumor angiogenesis 
and metastasis (10, 24, 25). VEGFR2 belongs to the receptor 
type tyrosine kinase gene family, and is involved in tumor 
angiogenesis, chemoresistance, and aorta survival (26). Currently, 
agents that target the VEGF (an activator of DLL4) pathway, 
such as bevacizumab, and inhibit angiogenesis are being used 
in the treatment of cancers; however, their efficacy is limited 
in some patients. Therefore, therapeutic strategies based on bispe-
cific antibody targeting DLL4 and VEGF holds great promise.
We first evaluated the effect of anti-DLL4 and ABL001 treat-
ment in twelve GC cell lines. Unexpectedly, anti-hDLL4 and 
ABL001 treatment could not effectively reduce the growth of 
majority of the GC cell lines growing as monolayers in culture 
dishes. Only AGS and MKN-28 cells showed a dose-dependent 
reduction in growth following treatment with these antibodies. 
However, both anti-hDLL4 and ABL001 had a significant effect 
on AGS and MKN-28 cells in 3D-culture reducing sphere for-
mation (indicative of stem-like cells). CSCs are responsible for 
tumor relapse, chemoresistance, and cancer metastasis (8, 27). 
Conventional chemotherapy offers limited benefits in advanced- 
stage GC patients and prognosis for such patients remains poor. 
Therefore, regulation of CSCs through the development of novel 
agents may improve the treatment and survival of GC patients. 
Notch signaling triggered by the interaction of DLL4 plays a 
crucial role in GC stem cell pathology (28). Here, we demon-
strate DLL4 inhibition using both anti-DLL4 and ABL001 signi-
ficantly reduced the stem-like phenotype in GC and anti-mouse 
mABL001 administration significantly reduced the tumor burden 
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in both xenograft and orthotopic GC-bearing mice.
Furthermore, we demonstrated the synergistic antitumor effect 
of combination treatment of ABL001 with irinotecan. Combined 
treatment of ABL001 with irinotecan synergistically reduced 
sphere formation of GC cell in a 3D culture compared to that 
by either single treatment. Further, this synergism was greater 
in in vivo GC-bearing mice. The combined administration of 
ABL001 with irinotecan reduced GC tumor burden compared 
to that by PBS or single agent administration alone. However, 
the molecular mechanisms involved in this synergistic anti-
tumor activity remain unclear and is the topic of our current 
research.
Collectively, our data suggest that DLL4 inhibition reduced 
the stem-like phenotype of cancer cells, and cancer cell migra-
tion and invasion. ABL001, a bispecific DLL4 and VEGF thera-
peutic antibody may be a promising agent in GC therapy, 
because it showed strong antitumor effect in vivo. Moreover, 
the combination treatment with irinotecan and ABL001 showed 
synergistic antitumor activity in GC-bearing mice, suggesting 
that combination treatment with irinotecan and ABL001 is a 
novel therapeutic approach in GC. However, further studies 
are needed for its application in GC therapy.
MATERIALS AND METHODS
Cell culture 
The human GC cell lines AGS, SCH, YCC-2, MKN28, MKN45, 
SNU216, SNU601, SNU638, SNU668, SNU719, SNU1750, 
NCC24, and N87 were obtained from KCLB (Seoul, Korea) 
and maintained in 1640 medium supplemented with 10% fetal 
bovine serum (FBS) and 1% antibiotics (Invitrogen, Carlsbad, 
CA, USA) at 37oC in an atmosphere of 5% CO2 as described 
previously (29, 30). Bispecific DLL4/VEGF antibody, ABL001 
(NOV1501/TR009) and irinotecan were obtained from ABL 
Bio (Pangyo, Korea).
3D cell culture assays
Cells (1,000 cells/ml) were grown in ultra-low attachment 
plates (Corning Costar, Acton, MA, USA) containing mammary 
epithelium basal medium (Lonza, Basel, Switzerland) supple-
mented with B27 (Gibco, Grand island, NY, USA), 20 ng/ml 
EGF, and 20 ng/ml bFGF (Peprotech, Rocky Hill, NJ, USA). 
After culturing for 15 days, spheres with diameters of ＞ 50 
m were counted (31).
Preparation of orthotopic transplanted GC-bearing mouse 
models
All animal experiments were approved by the Institutional Re-
view Board of the Yonsei University College of Medicine (IRB 
number: 2018-0155). The animals were maintained in specific 
pathogen-free facilities and used in accordance with the Uni-
versity’s Guidelines for the Care and Use of Laboratory Animals. 
Six-week-old female BALB/c nude mice (Orient, Korea) were 
subcutaneously inoculated with AGS luciferase cells (1 × 106/ 
100 l) in the flank side. Subcutaneous tumors were excised 
and implanted in the gastric wall of nude mice. Mice were 
randomized into groups (n = 5/group) and treatment was 
started 4 weeks after tumor implantation. Mice received 200 l 
PBS (as control), 3.25 mg/kg mouse surrogate ABL001, 10 
mg/kg irinotecan, or a combination of 3.25 mg/kg ABL001 and 
10 mg/kg irinotecan through intraperitoneal (i.p.) injection 
twice a week. Once every 2 weeks, the mice were injected i.p. 
with luciferin (Xenogen, Alameda, CA) and luciferase activity 
was recorded and measured using IVIS imaging. The experi-
ment was terminated at 5 weeks and the volumes of the ortho-
topically implanted tumors were calculated using the formula 
a2 × b× 0.5.
Statistical analysis
Unpaired (two sample) t test was used to determine the P- 
values. P-values ＜ 0.05 were considered to be statistically sig-
nificant. Statistical analyses were performed using Prism 5 
(GraphPad software, La Jolla, CA, USA).
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